Subsequent Events (Details)				1 Months Ended	3 Months Ended								12 Months Ended
	Aug. 03, 2018 USD ($)	Jul. 30, 2018 USD ($)	Jul. 13, 2018 USD ($)	Aug. 31, 2018 item	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)
Subsequent Events
Net sales					$ 139,118,000	$ 161,720,000	$ 170,944,000	$ 161,559,000	$ 168,887,000	$ 140,114,000	$ 127,059,000	$ 106,433,000	$ 684,563,000	$ 633,341,000	$ 542,493,000
Goodwill					339,566,000								339,566,000	339,566,000
Cash and cash equivalents					$ 117,737,000				$ 224,769,000				98,586,000	$ 117,737,000	$ 224,769,000	$ 200,340,000
Available borrowing capacity													125,000,000
JSP
Subsequent Events
Net sales													253,100,000
JSP | Levothyroxine Sodium Tablets
Subsequent Events
Net sales													$ 245,900,000
Gross Margin Percent													60.00%
Subsequent event
Subsequent Events
Total consideration of sale of real property			$ 14,600,000
Number of officers claiming damaged | item				2
Subsequent event | ANDOR Pharmaceuticals, LLC license agreement
License Agreement
Agreed amount of license		$ 1,500,000
License amount paid	$ 500,000
Amount to be paid upon approval by FDA		$ 1,000,000
Minimum royalty term		4 years
Royalty guaranty amount		$ 16,000,000
Reduction in the amount of royalty guaranty		$ 4,000,000